Analysts expect that Oxford Immunotec Global (NASDAQ:OXFD) will report earnings of ($0.42) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Oxford Immunotec Global’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.39). Oxford Immunotec Global reported earnings of ($0.36) per share in the same quarter last year, which would suggest a negative year over year growth rate of 16.7%. The firm is scheduled to announce its next earnings results before the market opens on Tuesday, May 1st.
On average, analysts expect that Oxford Immunotec Global will report full-year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($0.99) to ($0.94). For the next fiscal year, analysts forecast that the business will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.82) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Tuesday, February 27th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $25.03 million for the quarter, compared to the consensus estimate of $25.12 million. Oxford Immunotec Global had a negative return on equity of 42.38% and a negative net margin of 31.90%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.22) EPS.
Shares of OXFD traded down $0.41 during trading hours on Monday, reaching $12.53. The company’s stock had a trading volume of 53,390 shares, compared to its average volume of 145,381. The company has a market capitalization of $334.78, a price-to-earnings ratio of -9.21 and a beta of -0.32. Oxford Immunotec Global has a 1-year low of $10.00 and a 1-year high of $19.51. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.37 and a quick ratio of 4.92.
In related news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.11% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Oxford Immunotec Global by 5.4% during the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock worth $1,161,000 after purchasing an additional 3,507 shares during the period. New York State Common Retirement Fund boosted its position in Oxford Immunotec Global by 159.6% during the third quarter. New York State Common Retirement Fund now owns 57,895 shares of the company’s stock worth $973,000 after purchasing an additional 35,595 shares during the period. Wells Fargo & Company MN boosted its position in Oxford Immunotec Global by 31.3% during the third quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock worth $651,000 after purchasing an additional 9,235 shares during the period. Birchview Capital LP boosted its position in Oxford Immunotec Global by 64.7% during the fourth quarter. Birchview Capital LP now owns 127,303 shares of the company’s stock worth $1,778,000 after purchasing an additional 50,000 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Oxford Immunotec Global by 9.4% during the fourth quarter. Bank of New York Mellon Corp now owns 69,740 shares of the company’s stock worth $975,000 after purchasing an additional 6,017 shares during the period. Hedge funds and other institutional investors own 93.31% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.